Screener
TG Therapeutics TGTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-015246
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Investment in held-to-maturity securities | (21,063) | (92,059) |
| Purchases of equity investments | — | (1,250) |
| Purchases of property, plant and equipment | (51) | (25) |
| Net cash used in investing activities | (9,864) | (12,934) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Payment of loan payable | (255,000) | — |
| Proceeds from exercise of options | 763 | 21 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
Document
FAQ
- What is TG Therapeutics's investing cash flow?
- TG Therapeutics (TGTX) reported investing cash flow of -$9.86M in Q1 2026.
- How has TG Therapeutics's investing cash flow changed year-over-year?
- TG Therapeutics's investing cash flow increased by 23.7% year-over-year, from -$12.93M to -$9.86M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about TG Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude